Personalized T cell therapy for glioblastoma using engineered nanoparticles
Engineered Glioblastoma-specific T cells using Immunostimulatory Photothermal Nanoparticles
['FUNDING_OTHER'] · IMMUNOBLUE, LLC · NIH-11002528
This study is working on a new way to treat glioblastoma by using your own immune cells to better fight the tumor, with the hope that this personalized approach will help improve your treatment after surgery.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | IMMUNOBLUE, LLC (nih funded) |
| Locations | 1 site (BETHESDA, UNITED STATES) |
| Trial ID | NIH-11002528 on ClinicalTrials.gov |
What this research studies
This research aims to develop a personalized treatment for glioblastoma, the most common type of brain tumor, by creating T cells that specifically target the tumor. The approach involves using photothermal nanoparticles to heat and kill glioblastoma cells, which releases unique antigens. These antigens are then used to stimulate the patient's own immune cells, specifically T cells, to recognize and attack the tumor more effectively. The T cells are expanded in the lab and infused back into the patient after surgery, potentially improving treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are undergoing standard-of-care surgery.
Not a fit: Patients with other types of brain tumors or those who are not candidates for surgery may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for glioblastoma patients, potentially improving survival rates and quality of life.
How similar studies have performed: While the approach of using engineered T cells and photothermal therapy is innovative, similar strategies in targeting tumors have shown promise in other cancers, suggesting potential for success.
Where this research is happening
BETHESDA, UNITED STATES
- IMMUNOBLUE, LLC — BETHESDA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SWEENEY, ELIZABETH E — IMMUNOBLUE, LLC
- Study coordinator: SWEENEY, ELIZABETH E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.